DermAvance Acquires Hyalogy(TM) - Novel Nanotechnology for Skincare

Aug 16, 2006, 01:00 ET from DermAvance Pharmaceuticals, Inc.

    BERYWN, Pa., Aug. 16 /PRNewswire/ -- DermAvance Pharmaceuticals, a
 privately held pharmaceutical company specializing in advanced technology
 applications for skin health and cosmetic dermatology, today announced the
 acquisition of the North American rights for the Hyalogy(TM) Total Skin
 Care Line from Forlle'd in Japan.
     Hyalogy(TM) P-effect represents a novel breakthrough formulation
 technology, using a proprietary nanotechnology process, to create the first
 product for the cosmeceutical market that allows topically applied
 hyaluronic acid to penetrate the skin's epidermal barrier. The Hyalogy(TM)
 Total Skin Care Line is designed to provide deep hydration into the skin
 more effectively and for a prolonged period of time over current
 formulations of traditional skin moisturizers.
     The amount of moisture in skin, a source of youth and beauty, decreases
 with age. Hyaluronic acid, a naturally occurring substance produced by the
 body, is what gives skin its volume and fullness. Adults have only 1/20th
 of the amount of hyaluronic acid as a baby. Until now, hyaluronic acid had
 to be injected into the dermis because earlier formulations were not able
 to penetrate the skin topically. With extensive research efforts, using
 advanced infiltration nanotechnology, an ultra low molecular weight
 hyaluronic acid with superior ability to penetrate through to the deep
 layers of the skin has been created. Hyalogy(TM) P-effect conveys the
 extraordinary function of hyaluronic acid and delivers moisture deep
 beneath the skin surface without the use of needles. "The unique advantage
 of Hyalogy(TM) P-effect is its ability to penetrate deep beneath the skin's
 epidermal barrier," said W. Philip Werschler, MD/FAAD, board certified
 dermatologist and Assistant Clinical Professor at the University Of
 Washington School Of Medicine.
     "The introduction of cosmeceutical nanotechnology will not only
 significantly effect cosmeceutical formulations but may very well
 revolutionize drug delivery systems in a number of key areas," commented
 Keith Greathouse, President and CEO of DermAvance. "We are very excited
 about our collaboration with Forlle'd, who is at the forefront of
 nanotechnology development in cosmetic dermatology and innovative
 cosmeceutical formulations. We expect to launch the Hyalogy(TM) Total Skin
 Care Line early in the 4th Quarter of 2006."
     About DermAvance Pharmaceuticals, Inc.
     DermAvance Pharmaceuticals, Inc. is a privately held dermatology
 pharmaceutical company focused on commercializing unique, and innovative
 anti- aging products to enhance the health and appearance of skin. The
 company was founded to meet the rapidly growing demand for facial skin
 rejuvenation products. DermAvance expects to launch several unique product
 lines in the 4th Quarter of 2006, including Vivelif(R) (acetyl
 hexapeptide-3), an innovative topical peptide preparation designed to
 reduce the visible signs of aging by targeting biochemical mechanisms of
 wrinkle formation similar to the activity of neurotoxins. DermAvance
 markets and sells products directly to dermatologists and aesthetic
 physicians for in-office dispensing.
     For additional information contact:
     Kathleen Sugg (610) 727-3959 Keith Greathouse (610) 727-4066
     Vice President of Marketing President & CEO

SOURCE DermAvance Pharmaceuticals, Inc.